CA-JUNIPER-NETWORKS
Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Korian Benelux, part of a major European healthcare and long-term elderly care organization, selected Juniper’s AI-driven enterprise solutions, including wireless and wired access, to optimize network performance and reliability and deliver personalized care for its residents.
More than 11 thousand Korian employees provide care for approximately 15 thousand residents in 173 locations in The Netherlands and Belgium. Korian was drawn to the Mist AI engine with cloud-hosted operations to give its IT team greater insights into user experiences and better troubleshooting for connected medical Wi-Fi devices and phones. The real-time insights, provided by Juniper Mist Wired Assurance, Juniper Mist Wireless Assurance and the Marvis™ Virtual Network Assistant, have simplified troubleshooting at the customer, device and site level for better service quality. By leveraging Mist AI, the Juniper solution delivers customizable service levels and actionable recommendations to proactively fix issues, often before users are impacted. As a result, users experience a more reliable network infrastructure with less downtime, due to the Juniper Mist AI predictive approach. Centralized configuration and zero-touch provisioning simplify onboarding new Juniper access points and switches as facilities are updated. When Korian does a renovation, the network can be installed in one day, compared to two days with their previous wireless solution.
Staying connected to families and friends is important to the well-being of Korian’s residents and short-term recovery patients, whether they like to call, video chat or email. Residents can use tablets in their rooms to watch movies, listen to their favorite music and call the nursing staff if they need help. Voice communications are loud and clear. Families and friends have guest Wi-Fi when they come to visit.
Korian staff have fast, responsive access to their long-term care, clinical and administrative applications, so they can stay productive and focused on patient care. Smart medical devices have the more reliable connectivity necessary for Korian to provide optimal care.
The organization adopted Juniper Wireless Access Points and Wireless Assurance driven by Mist AI to deliver better resident engagement, coupled with industry-leading Wi-Fi that is both more predictable and more reliable. In addition, Juniper Networks EX Series Switches and Juniper Mist Wired Assurance provide high-performance, more secure access to the access points and other wired devices. Juniper was named a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure.
Korian Benelux Group worked with Nomios, a Juniper Elite Plus partner, to create the optimal network architecture, focusing on network design, validation and testing to ensure that the Juniper solutions met strategic and technical goals.
Supporting Quotes:
“With our new network, our nursing staff have resilient access to medical and administrative applications. Computers on wheels and other smart medical equipment are always connected. Residents and their families can now easily connect to the Wi-Fi. IT has clear visibility into service level expectations and what we’re actually delivering. With Juniper Mist, we can see any Wi-Fi problems ourselves immediately, instead of waiting for nursing staff to tell us. Ultimately, we spend less time troubleshooting, and that frees up our time for more strategic priorities.”
- Christoph Van Doren, ICT Director, Korian Benelux
“Healthcare organizations are constantly looking to leverage innovative technology to deliver a high-touch experience for residents, guests and staff. The network plays a vital role at Korian by keeping its technology infrastructure healthy. It allows them to simply scale and support new applications and technologies that can assist in driving better resident outcomes and experiences.”
- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks
Additional Resources:
- Korian: Success Story
- 2022 Gartner Magic Quadrant for Enterprise Wired and Wireless LAN Infrastructure: View Report
- Blog: When it Comes to Wired & Wireless Access, Juniper Mist is in the Driver’s Seat
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005106/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
